Selective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
- 30 September 2001
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 53 (3), 247-264
- https://doi.org/10.1016/s0169-409x(01)00206-x
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Comparison of Recombinant and Synthetically Formed Monoclonal Antibody-β-Lactamase Conjugates for Anticancer Prodrug ActivationBioconjugate Chemistry, 1999
- A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPTBioorganic & Medicinal Chemistry Letters, 1999
- Synthesis of α-aminoacyl derivatives of melphalan for use in antibody directed enzyme pro-drug therapyTetrahedron, 1999
- Development and Activities of a New Melphalan Prodrug Designed for Tumor-Selective ActivationBioconjugate Chemistry, 1998
- Construction, Expression, and Activities of L49-sFv-β-Lactamase, a Single-Chain Antibody Fusion Protein for Anticancer Prodrug ActivationBioconjugate Chemistry, 1997
- Accelerated clearance systemsAdvanced Drug Delivery Reviews, 1996
- First clinical experience with ADEPTAdvanced Drug Delivery Reviews, 1996
- Sulfated etoposide and nitrogen mustard prodrugs and their activation by streptomyces arylsulfataseDrug Delivery, 1995
- Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugateBioconjugate Chemistry, 1993
- Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compoundsEuropean Journal of Cancer and Clinical Oncology, 1991